Macresia Braziel
Family · Fort Pierce, FLNPI 1124493432
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $874 and has fallen 89.0% since, to $96 in 2025.
Across 92 payments — averaging $30.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$413
- Amgen$312
- AstraZeneca$293
- Novo Nordisk$234
- Mallinckrodt Hospital Products Inc.$196
- Alnylam Pharmaceuticals Inc.$126
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,68397%
- Education$853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 13 | $413 |
| Amgen(2 entities) | 10 | $312 |
| AstraZeneca | 12 | $293 |
| Novo Nordisk | 7 | $234 |
| Mallinckrodt Hospital Products Inc. | 13 | $196 |
| Alnylam Pharmaceuticals Inc. | 5 | $126 |
| AbbVie | 1 | $125 |
| Medtronic | 1 | $125 |
| Gilead | 1 | $122 |
| Janssen Products, LP | 1 | $122 |
| Johnson & Johnson | 1 | $113 |
| ANI Pharmaceuticals, Inc. | 5 | $80 |
| Rhythm Pharmaceuticals, Inc. | 1 | $75 |
| Lilly USA, LLC | 4 | $72 |
| Calliditas Therapeutics US Inc. | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Exact Sciences | 2 | $47 |
| Cranial Technologies, Inc | 2 | $36 |
| Fresenius USA Marketing, Inc. | 1 | $23 |
| Amicus Therapeutics, Inc. | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
| Sanofi | 1 | $17 |
| Pfizer | 1 | $17 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,768 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate | 19 | $60 |
| Lisinopril | 11 | $10 |
Paid to pharmacies, not to this prescriber.
Other family in Fort Pierce
- Marta EuleFort Pierce$91K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.